Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• The cytokine LIGHT exhibits anti-tumor properties by engaging lymphotoxin beta receptor (LTbetaR) and herpes virus entry mediator (HVEM).
• Decoy receptor 3 (DcR3), often overexpressed in tumors, neutralizes LIGHT, limiting its therapeutic efficacy.

Purpose of the Study:

• To develop LIGHT mutants that specifically bind LTbetaR and HVEM but are resistant to DcR3 binding.
• To optimize LIGHT-based cancer therapy by overcoming DcR3-mediated inhibition.

Main Methods:

• Phage display technique was employed to generate a library of LIGHT mutants with randomized amino acid residues.
• Affinity panning was used to select LIGHT variants with altered binding characteristics.
• Binding affinities and kinetics for interactions with LTbetaR, HVEM, and DcR3 were analyzed.

Main Results:

• Six LIGHT mutant clones were identified with significantly reduced affinity for DcR3 (10-fold lower than wild-type).
• Five mutants maintained comparable binding affinities for LTbetaR and HVEM.
• Mutants exhibited faster off-rates from DcR3, leading to a 62-fold increase in DcR3-evading capacity.
• One mutant demonstrated similar cytotoxicity via LTbetaR as wild-type LIGHT.

Conclusions:

• Engineered LIGHT mutants effectively evade DcR3 inhibition while preserving essential receptor interactions.
• These DcR3-evading LIGHT variants represent promising candidates for enhanced cancer immunotherapy.
• The study provides a foundation for developing more potent LIGHT-based therapeutic agents.